Baker Hughes offers EU concessions to push Chart deal forward

What happened

Baker Hughes has formally submitted remedy proposals to the European Commission to secure antitrust approval for its $13.6 billion acquisition of Chart Industries, a procedural step aimed at addressing competition concerns in cryogenic and process technology markets. The move comes as the company trades at a rich ~21x trailing EPS, a multiple that already assumes smooth integration and rapid de-leveraging to 1.0-1.5x net debt/EBITDA. The DeepValue master report flags that the deal increases capital intensity and balance-sheet risk at a time when OFSE margins are contracting and IET order momentum is critical to sustaining the valuation. The remedies offer a glimpse of potential integration hurdles, reinforcing the view that expected returns from the current ~$57 price are skewed to the downside. While the regulatory process is expected, any mandatory divestitures could reduce synergy potential and delay closing, adding uncertainty to an already stretched setup.

Implication

Investors should monitor the specific remedies offered, as any mandatory divestitures could reduce synergy potential and delay the deal's closing. The acquisition's success hinges on achieving $325 million in annual cost savings within three years while keeping net leverage under 2.0x, and regulatory concessions may narrow the path to those targets. With the stock pricing in a near-ideal scenario of sustained IET orders and flawless integration, any sign of friction creates asymmetric downside risk. The regulatory step is a reminder that execution risk is real and the margin of safety is thin given the premium valuation. Until clearer evidence of smooth integration and sustained IET order momentum emerges, we recommend a cautious stance and suggest trimming into strength.

Thesis delta

The offer of remedies confirms the deal is progressing but introduces potential constraints on strategic scope, reducing the probability of a flawless integration. While not a thesis breaker, it adds regulatory uncertainty to an already stretched valuation and strengthens the case for the current 'POTENTIAL SELL' rating. Investors should reassess if remedies force material asset sales or significantly delay closing.